To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

NCT06756269 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV Infection
HPV-Related Carcinoma
HPV-Related Intraepithelial Neoplasia
Genital Wart

Interventions

BIOLOGICAL: Medium dose for 15-HPV vaccine
BIOLOGICAL: High dose for 15-HPV vaccine
BIOLOGICAL: Placebo
BIOLOGICAL: 9-HPV vaccine

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.